Abstract: Precision therapy, represented by cancer targeted drugs, is bringing revolutionary breakthroughs to treatment. Acute promyelocytic leukemia (APL), formerly defined as a highly lethal hematological malignancy, can now be mostly cured by precision diagnosis and treatment based on clarification of molecular pathogenesis. Recently, prospective multicenter randomized controlled clinical trial, precise scoring system, PML-RARa directed target atlas regulated by synergistic treatment can further help us overcome the remaining obstacles of high risk APL cure. This concept could extend to other types of leukemia or solid tumors.

Key words: tumor; precision therapy; acute promyelocytic leukemia